Loading…
Loading…
Home › All recalls › Prescription medicine
Category
Prescription drugs recalled for contamination, potency or labelling.
Or try another category
2,003 recalls · newest first
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Why this is here: It was found to contain a drug or chemical that is not on the label. That is different from an allergen or a contamination scare: anyone taking it has been taking a substance nobody prescribed, in an unknown dose, and it can interact with medication they are already on. Follow the agency notice rather than judging it by how the product looks.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Why this is here: It was found to contain a drug or chemical that is not on the label. That is different from an allergen or a contamination scare: anyone taking it has been taking a substance nobody prescribed, in an unknown dose, and it can interact with medication they are already on. Follow the agency notice rather than judging it by how the product looks.
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Why this is here: It was found to contain a drug or chemical that is not on the label. That is different from an allergen or a contamination scare: anyone taking it has been taking a substance nobody prescribed, in an unknown dose, and it can interact with medication they are already on. Follow the agency notice rather than judging it by how the product looks.
Labeling: Label mix-up - ephedrine syringes mislabeled as phenylephrine.
Presence of Foreign Tablets: Pharmacist reported a tablet of baclofen in a bottle of 1000-count tramadol
Presence of Particulate Matter: Potential for black particulates in the drug product.
Defective Container: yellow-colored spike from cap lodged in the nozzle.
Failed Tablet/Capsule Specifications: There is a potential for the imprint, M 122, to be missing on some tablets.
Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.
Presence of Foreign Substance; Broken metal piece found embedded in tablet.
Presence of Foreign Substance: This oil based product may contain trace amounts of water for injection (WFI).
Discoloration: Dotted and yellow spots on tablets
Subpotent drug
Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.
Discoloration: Dotted and yellow spots on tablets
CGMP Deviation: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity…
Lack of Assurance of Sterility: Complaints of syringe breakage
CGMP Deviation: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity…
CGMP Deviation: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity…
Failed Release Testing: Out of specification for particulate matter test.